Exelixis Downgrade Looks Like Noise: The Real Story Is the Aug. 5 Sales Check

Leerink's downgrade looks more like a reset than a warning shot

Leerink's "Market Perform" downgrade is easier to overreact to than the underlying numbers suggest. The firm set a $52 price target, implying roughly 1.1% downside, while the broader Wall Street consensus still sits at "Hold" with a $49.79 average target. That is not the profile of a business that has suddenly broken.

More important, the downgrade came after Exelixis had already given investors the operating update that matters. On Aug. 5, the company reported $806 million of global cabozantinib revenue, about $629 million of Q2 revenue, and an update on progress toward achieving key corporate objectives. So the market was not reacting to a surprise; it was reacting to a rating label on top of numbers it had already seen.

That narrows the debate. Bulls can point to a still-functioning core business and a franchise generating solid revenue. Bears do not need cabozantinib to fail; they only need to argue the stock does not offer enough upside at today's setup. That is mainly a valuation debate, not evidence that the commercial engine suddenly cracked.

Exelixis commercial run-rate still looks healthy

The quarter's revenue line held up

Exelixis delivered $628.7 million of Q2 revenue, including $573.0 million of U.S. cabozantinib net product revenue. That is a solid commercial read. The quarter still looks like a business executing, not one trying to dress up weak demand with accounting niceties or minor mix shifts.

There is at least one valid watchpoint. Exelixis reported a 29.5% gross-to-net adjustment and kept full-year guidance at 30% to 31%. That does not mean the franchise is breaking; it does mean investors should keep an eye on whether gross-to-net stays contained or starts to widen. For now, the figure looks more like a normal pressure point for a launched oncology franchise than a sign of collapsing demand.

Management also emphasized three things that matter: continued growth in the cabozantinib franchise, disciplined expense management, and returning capital to shareholders. The repurchase activity stands out. Exelixis completed approximately $312 million of common stock repurchased in Q2 2026, retiring approximately 6.5 million shares. That does not guarantee upside, but it does suggest management still sees an operating business worth supporting.

Pipeline optionality is still the bigger catalyst

The commercial base appears stable, but the reason investors may pay more for Exelixis in the future is pipeline diversification. At ASCO, the company highlighted data across neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors, reinforcing that cabozantinib still has exploration value beyond its established uses.

The more meaningful upside, though, sits with zanzalintinib. Management's Aug. 5 update still framed the molecule as a potential next franchise asset and pointed to a possible approval pathway in metastatic colorectal cancer later this year. If that program advances, Exelixis starts to look less like a one-drug story and more like a company with a credible successor candidate.

The restructuring looks more like consolidation than distress

The simpler headline around the reorganization was winding down the Pennsylvania site and reducing head count. But the context matters. Management described the move as a consolidation around Alameda, with the goal of focusing effort on cabozantinib, zanzalintinib, and the early pipeline.

That is a different read from "distress." It looks more like org-chart simplification. The real question is whether the change improves execution without slowing clinical progress or commercial momentum.

Valuation and proof points matter more than the downgrade headline

At 13.28 Forward P/E and a balance sheet with about $3.09 cash per share, Exelixis does not look priced like a broken biopharma name. Add approximately $1.4 billion as of June 30, 2026 in cash and marketable securities, and the company still has room to fund operations, support shareholder returns, and wait for pipeline catalysts.

The next proof points are straightforward:

• Cabozantinib durability: management still said Q2 showed the continued growth of the cabozantinib franchise.
• Gross-to-net discipline: whether the 29.5% Q2 figure stays close to the 30% to 31% full-year guide.
• Zanzalintinib progress: whether the molecule moves closer to a meaningful regulatory milestone.
• Cost control: whether the restructuring helps contain operating expenses without slowing execution.

For now, the downgrade looks more like a positioning reset than a fundamental break. The core business still appears intact, the balance sheet still looks comfortable, and the next move in the stock likely depends more on commercial durability and pipeline proof than on a single rating change.